News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Werewolf Therapeutics, Inc. (NasdaqCM:HOWL) has a market cap of US$18.6m and its stock price recently dropped by 68.03% over seven days. The company is developing various biopharmaceutical therapeutics for cancer and immune-mediated conditions using its PREDATOR platform. Major risks include high share price volatility …
This article provides a financial data point for Werewolf Therapeutics, Inc. (NASDAQ: HOWL), specifically its price-to-sales forward ratio. The content appears to be a stub or a data-only entry from a financial platform like TradingView, with no further analysis or contextual information. It primarily …
Wolfspeed (WOLF) has announced a partnership with LITEON to provide silicon carbide power solutions for next-generation AI data centers, leveraging its 200mm silicon carbide platform. This collaboration aims to meet the demand for efficient and reliable power delivery in hyperscale AI and cloud environments. …
Jane Street Group, along with its subsidiaries, has disclosed a 4.4% beneficial ownership in Wolfspeed, Inc. (NYSE: WOLF) through an amended Schedule 13G filing. This holding amounts to 2,272,164.43 shares, with all voting and dispositive authority shared among the Jane Street entities. The ownership …
Wolfspeed, Inc. and LITEON Technology Corporation have announced a strategic partnership to integrate Wolfspeed's silicon carbide technology into LITEON's 800 VDC power solutions for next-generation AI data centers. This collaboration aims to provide highly efficient and scalable power delivery for hyperscale customers, leveraging Wolfspeed's …
Wolfspeed, Inc. has announced that it will release its fiscal fourth quarter financial results on Wednesday, August 19, 2026, before the market opens. The company will also host a conference call at 8:00 a.m. EDT on the same day to discuss these results.
Wolfspeed, Inc. (NYSE: WOLF) announced that its CEO, Robert Feurle, and CFO, Gregor van Issum, will host a conference call and audio webcast on Wednesday, August 19, 2026, at 5:00 pm Eastern Time to discuss the company's fourth quarter and full fiscal year 2026 …
This article focuses on the enterprise value to revenue forward metric for Werewolf Therapeutics, Inc. (NASDAQ: HOWL). It appears to be a financial data point presented by TradingView, indicating a specific valuation ratio for the pharmaceutical company. The content itself is minimal, primarily highlighting …
Werewolf Therapeutics reported that as of June 30, their cash and cash equivalents stood at $22 million. This financial update indicates the company's liquid assets at the end of the second quarter.
Werewolf Therapeutics (HOWL) reported Q2 2026 financial results, including $21.0 million in collaboration revenue and $3.7 million net income, primarily from selling its JZP898 program. The company also announced repayment of its loan with K2 HealthVentures and is exploring strategic alternatives, with updates expected …
Werewolf Therapeutics, Inc. reported a significant turnaround in 2Q 2026, recognizing $21 million in collaboration revenue and achieving a net income of $3.67 million, or $0.08 diluted EPS, compared to a net loss in the prior year. This improvement was driven by the upfront …
Werewolf Therapeutics (Nasdaq: HOWL) announced its financial results for the second quarter ended June 30, 2026, including a net income of $3.7 million, a significant improvement from a net loss in the prior year. The company's cash and cash equivalents stood at $22.0 million, …
Werewolf Therapeutics Inc (HOWL) has a risk assessment score of 1.54, ranking 285 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 0.32, indicating it tends to underperform during upward markets but experiences smaller declines during downward trends. …
Werewolf Therapeutics (HOWL) reported Q2 2026 earnings on July 31, 2026, with an EPS of $0.08, significantly beating analysts' consensus of -$0.28. The company's revenue for the quarter was $21 million, meeting the consensus estimate. Werewolf Therapeutics' next Q3 earnings are estimated for August …
Wolfspeed, Inc. announced the appointment of Andy W. Mattes to its board of directors, effective immediately. Mattes brings over 40 years of experience in the semiconductor and advanced technology industries, having served as CEO of Coherent and Diebold Nixdorf, and held senior leadership positions …
Wolfspeed, Inc. announced the immediate appointment of Andy W. Mattes to its Board of Directors. Mattes brings over 40 years of leadership experience in the semiconductor and advanced technology industries, having served as CEO of Coherent and Diebold Nixdorf, and held senior roles at …
Wolfspeed, Inc. (NYSE: WOLF) announced the appointment of Andy W. Mattes to its Board of Directors, bringing over 40 years of leadership experience in the semiconductor and advanced technology industries. Mattes, a former CEO of Coherent and Diebold Nixdorf, is expected to contribute his …
This article provides a comprehensive stock analysis of Werewolf Therapeutics Inc (HOWL) by TradingKey, detailing its fundamentals, valuation, and market performance. Key insights indicate healthy fundamentals, high growth potential, and a 'Buy' rating from multiple analysts despite an expected medium-term downward trend. The analysis …
This article provides an overview of Werewolf Therapeutics Inc (HOWL)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and lists basic financial data such as its market capitalization and current stock price. …
Wolfspeed Inc. (WOLF) stock is currently trading at $23.09, down 11.02% from its previous close. Its fundamentals are stable with good growth potential, but its valuation is considered fairly valued, and analysts have recently rated it as "Sell." The stock has experienced a significant …
This article provides an overview of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) financials on TradingView. It indicates that the market was closed with no trades. The content primarily outlines the navigation structure and available financial data categories on the TradingView platform for this company.
Werewolf Therapeutics Inc (HOWL) currently has a valuation score of 7.06, placing it 270 out of 386 in the Biotechnology & Medical Research industry. Its P/E ratio is -0.36, which is significantly below its recent high but above its recent low. The company has …
This article provides a financial health analysis of Werewolf Therapeutics Inc (HOWL), ranking its financial score at 6.80 within the Biotechnology & Medical Research industry. It indicates robust financial status but low operating efficiency. The analysis highlights that relevant data for various financial dimensions …
Wolfspeed stock is under investor scrutiny as the company experiences widening losses due to substantial capital expenditures for new silicon carbide manufacturing facilities, despite significant revenue growth. The company's strategy focuses on silicon carbide materials and power devices for the electric vehicle and industrial …
HOWL stock, tied to Werewolf Therapeutics, Inc., is gaining attention in the context of its latest investor materials and general market sentiment. The company, a Nasdaq-listed biotech, focuses on next-generation immunotherapies, and its stock performance is primarily driven by its pipeline depth, trial timing, …
Werewolf Therapeutics (HOWL) stock is trading based on recent clinical trial updates and financial results. The company reported increased revenue from collaborations but also higher R&D expenses, leading to a net loss of $60 million in fiscal 2024. Despite this, a cash reserve of …
Search by ticker symbol or company name and select a result to open its chart.